General session III and award ceremony II

 General hepatology

Main Plenary
13 April 2019 10:00 - 12:00


GS-13 Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of bulevirtide (Myrcludex B) in with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection
Heiner Wedemeyer - Germany
13 April 2019 10:00 - 10:15

GS-14 ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients
Manisha Balwani
13 April 2019 10:15 - 10:30

GS-15 Deficiency of the ABC transporter ABCC12/MRP9 is associated with chronic cholestasis syndromes and causes bile duct paucity in zebrafish and mouse model organisms
Lingfen Xu - United States
13 April 2019 10:30 - 10:45

Award ceremony II
13 April 2019 10:45 - 11:15

GS-16 Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: A European phase I/IIa open-labelled study
Frederik Nevens - Belgium
13 April 2019 11:15 - 11:30

GS-17 The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB
Romina Salpini - Italy
13 April 2019 11:30 - 11:45

GS-18 Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival
Christophe Corpechot - France
13 April 2019 11:45 - 12:00